NICE
Guideline
May 2019
For professionals
NICE's guideline for the NHS in England on managing Crohn's in children, young people and adults. It covers giving people information and support, treatment to bring Crohn's under control and keep it there, surgery, keeping remission after surgery, checking bone health, and pregnancy. It is about care after diagnosis rather than how Crohn's is diagnosed.
Topics
About Crohn's disease
Medicines
Surgery
Monitoring
Pregnancy and fertility
Children and young people
Steroids
Immunosuppressants
Jargon explained
remission
inducing remission
maintaining remission
osteopenia
NICE guideline
induce remission
maintain remission
glucocorticosteroid
thiopurine
TPMT
resection
stricture
The Lancet
Study
May 2022
For professionals
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
Topics
Biologics and newer medicines
Research
Jargon explained
IL-23
maintenance
placebo
endoscopic response
Cochrane
Systematic review
Aug 2018
Patients and professionals
Asks whether supplement drinks help keep Crohn's quiet once it has settled. The results are too uncertain to say either way, and the reviewers call for more research.
Topics
Diet and nutrition
Jargon explained
enteral nutrition
maintenance
quiescent
Cochrane
Systematic review
May 2020
Patients and professionals
Cochrane concluded that adalimumab works for keeping Crohn's in remission, including in people who had already tried another anti-TNF drug. Whether it helps after bowel surgery is still unclear.
Topics
Biologics and newer medicines
Jargon explained
anti-TNF
maintenance
quiescent
Cochrane (via PMC)
Systematic review
Aug 2014
Patients and professionals
A Cochrane review concluding that budesonide does not keep Crohn's in remission, especially beyond three months. Small benefits were outweighed by more side effects and adrenal suppression.
Topics
Steroids
Research
Jargon explained
budesonide
maintenance
adrenal suppression
Cochrane
Systematic review
Feb 2019
Patients and professionals
A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.
Topics
Diet and nutrition
Research
Jargon explained
remission
exclusion diet
randomised controlled trial
Cochrane
Systematic review
Jul 2023
Patients and professionals
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics
Biologics and newer medicines
Research
Jargon explained
high-certainty evidence
induction
maintenance
integrin
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo
Cochrane
Systematic review
Feb 2019
Patients and professionals
Antibiotics may give a small benefit for active Crohn's, but probably not enough to make a real difference for most people. They did not cause more side effects than placebo. Whether they help keep Crohn's in remission is unclear. Note this is about treating the Crohn's itself, not infections or abscesses.
Topics
Medicines
Research
Jargon explained
antibiotic
clinically meaningful
antibiotics
induction
maintenance
The Lancet Gastroenterology & Hepatology
Study
Jan 2022
Patients and professionals
A small pilot trial of 44 adults with mild to moderate Crohn's who had not had biologics. The CDED, with or without supplement drinks, put more than half into remission at 6 weeks, and most of them were still in remission at 24 weeks. About a third had a healed bowel lining. The authors say a bigger trial is needed before firm conclusions.
Topics
Diet and nutrition
Jargon explained
pilot study
open-label
endoscopic remission
Cochrane (via PMC)
Systematic review
Aug 2014
Patients and professionals
A Cochrane review finding moderate-quality evidence that methotrexate given by injection helps keep Crohn's in remission and appears safe, while low-dose tablets did not appear effective in the trials reviewed. Adding methotrexate to infliximab did not improve remission rates.
Topics
Immunosuppressants
Research
Jargon explained
methotrexate
intramuscular
maintenance
Cochrane
Systematic review
Oct 2015
Patients and professionals
Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.
Topics
Immunosuppressants
Research
Jargon explained
thiopurine
low-quality evidence
adverse event
remission
placebo
systematic review